Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of LBVE vs Prevnar13 in Healthy Adults
NCT03549208Phase 1Unknown
- Sponsor
- LG Chem
- Start
- Jul 2018
- Primary completion
- Apr 2019
- Modality
- Split/Subunit Vaccines
01
Overview
Phase 1, randomised, single-blind trial of LBVE013 in pneumococcal infection (3 arms), sponsored by LG Chem. Primary endpoints: Solicited adverse events at 7 days, Unsolicited adverse events at 4 weeks and 1 more. Status: unknown.
02
Drugs
LBVE013
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT03549208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03549208.